Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : Oklahoma presents final witness in trial against drug makers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/26/2019 | 11:02am EDT

NORMAN, Okla.Oklahoma is wrapping up its presentation of evidence against Johnson & Johnson in the state's case alleging the consumer products giant and its subsidiaries helped fuel the deadly opioid crisis.

Attorneys for the state on Wednesday continued questioning Oklahoma Department of Mental Health and Substance Abuse Services Director Terri White. She is the state's final witness.

Oklahoma alleges opioid drug makers caused a public nuisance in Oklahoma by promoting widespread use of the highly addictive drugs and that abatement will cost billions. The trial began May 28 and is expected to continue for several more weeks as the defence presents its case. The company maintains it has acted responsibly.

Connecticut-based Purdue Pharma and Israeli-owned Teva Pharmaceuticals previously settled with the state for $270 million and $85 million , respectively.

© 2019 The Canadian Press. All rights reserved., source Canadian Press DataFile

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12:42pJOHNSON & JOHNSON : Oklahoma judge expected to rule Monday in opioid case
AQ
08/19JOHNSON & JOHNSON : Congo to use second vaccine to fight Ebola
AQ
08/16JOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
08/16JOHNSON & JOHNSON : Ebola Crisis-The Vaccines Debate
AQ
08/15JOHNSON & JOHNSON : Janssen Announces European Commission Approval of Imbruvica ..
AQ
08/13JOHNSON & JOHNSON : J&J's Janssen Gets EC OK for Expanded Use of Imbruvica
DJ
08/12JOHNSON & JOHNSON : Thinking about trading options or stock in AbbVie, Bristol-M..
PR
08/12JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTURO ..
AQ
08/09JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTUROÒ..
PU
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
RE
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 6 547 M
Yield 2019 2,88%
P/E ratio 2019 19,4x
P/E ratio 2020 17,2x
EV / Sales2019 4,30x
EV / Sales2020 4,03x
Capitalization 345 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 148,50  $
Last Close Price 130,60  $
Spread / Highest target 29,4%
Spread / Average Target 13,7%
Spread / Lowest Target -5,05%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.48%344 675
ROCHE HOLDING LTD.12.16%238 287
MERCK AND COMPANY12.09%219 296
NOVARTIS17.97%204 985
PFIZER-19.40%191 430
AMGEN4.37%121 841